Dark

Check out our Dark Pool Levels

XRTX
XORTX Therapeutics Inc. Common Stock
stock NASDAQ

Market Open

May 8, 2025 3:59:30 PM EDT

1.03USD0.000%(0.00)2,505

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 6, 2025 8:00:30 AM EDT

0.9975USD-3.155%(-0.0325)0

After-hours

May 7, 2025 4:44:30 PM EDT

1.01USD0.000%(+1.01)0

OverviewHistoricalExchangesShortsNews

Jan 31, 2022

07:00AM EST XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to take this opportunity to provide an update on the Companys progress in 2021 and provide insights on 2022 goals. GlobeNewswire Inc

Jan 20, 2022

07:00AM EST XORTX Announces Appointment of Chief Technology Officer GlobeNewswire Inc

Jan 10, 2022

07:00AM EST XORTX to Participate in H.C. Wainwright BioConnect 2022 Virtual GlobeNewswire Inc

Dec 21, 2021

06:00PM EST XORTX Reports Annual & Special Meeting Results GlobeNewswire Inc

07:00AM EST XORTX Therapeutics Announces Filing of Provision Patent for GlobeNewswire Inc

Dec 10, 2021

07:01AM EST XORTX Therapeutics Announces Publication of Mt. Sinai Study of GlobeNewswire Inc

Dec 9, 2021

09:50PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 Benzinga

09:48PM EST Alliance Global Partners Initiates Coverage On XORTX Therapeutics with Buy Rating, Announces Price Target of $11 Benzinga

09:30AM EST TMX Group Equity Financing Statistics - November 2021 PR Newswire

08:04AM EST XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announced today that James Molloy, Senior Biotechnology Analyst at A.G.P./Alliance Global Partners, has initiated research coverage on XORTX. GlobeNewswire Inc

Dec 2, 2021

07:00AM EST XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study GlobeNewswire Inc

Nov 23, 2021

07:00AM EST XORTX Therapeutics Announces Annual and Special Meeting of GlobeNewswire Inc

Nov 15, 2021

08:01AM EST Argus Research Initiates Equity Research Report Coverage on XORTX Therapeutics PR Newswire

Nov 9, 2021

07:00AM EST XORTX Therapeutics Announces Partial Exercise of Over-Allotment GlobeNewswire Inc

Nov 5, 2021

08:12AM EDT IIROC Trading Resumption - XRTX PR Newswire

Nov 4, 2021

08:19AM EDT IIROC Trading Halt - XRTX PR Newswire

Oct 15, 2021

05:38PM EDT XORTX Therapeutics Announces Closing of US$12 Million Public Offering GlobeNewswire Inc

Oct 14, 2021

07:00AM EDT XORTX Therapeutics Inc. ("XORTX" or the Company) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the LD Micro Main Event, being held October 12 through 14, 2021. GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT Mid-Morning Market Update: Markets Mixed; JPMorgan Posts Upbeat Earnings Benzinga

07:55AM EDT XORTX Therapeutics Announces Pricing of US$12 GlobeNewswire Inc

Share